Adtran FSP 3000 OLS plays key role in OIF’s largest-ever demo at OFC
22.3.2024 16:00:00 EET | Business Wire | Press release
Adtran today announced that it’s playing a key role in the Optical Internetworking Forum’s (OIF) most extensive multi-vendor interoperability demo to date, held at the Optical Fiber Communication Conference and Exhibition (OFC). Central to the showcase is Adtran’s FSP 3000 open line system (OLS), which delivers 400Gbit/s OpenZR+ transceiver interoperability across a 1,000km link. The OLS features advanced automation and optimization for maximum performance and user-friendly operation. Involving 47 member companies, the demo marks a major milestone in open networking and highlights the commitment of the OIF community to driving the future of high-performance, efficient and scalable network solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240322753779/en/
Adtran’s FSP 3000 OLS is playing a central role in the OIF’s biggest interoperability demo to date. (Photo: Business Wire)
“Interoperability continues to be at the heart of our vision for the future of optical networking. This year, by showcasing our FSP 3000 OLS’s capacity for 400Gbit/s OpenZR+ transceiver interoperability over regional distances, we’re pushing the boundaries of end-to-end network performance,” said Stephan Neidlinger, VP of global business development at Adtran. “Together with our fellow industry innovators at the OIF, we’re spotlighting what can be achieved when we unite behind intelligent, open architectures. This shared dedication to supporting multi-vendor environments will ensure superior network performance and new levels of flexibility for our customers.”
The demo uses Adtran’s FSP 3000 OLS to interconnect 400Gbit/s OpenZR+ pluggable transceivers from different suppliers over a bidirectional link that extends up to 1,000km. This comprises eight spans and utilizes Corning’s SMF-28 ULL and Contour fibers. The setup uses compact amplification modules integrating EDFA and Raman amplification, OSC, monitor ports and auto-span equalization. This enables an OLS configuration with a high degree of integration, performance, automation and ease of use. It also features terminal nodes with flexible multi-degree ROADMs for power equalization and scalability. The configuration provides an open hardware platform with programmable interfaces that pave the way for interoperability across various data rates, modulation formats and upgrades to 800Gbit/s transport.
“This demo is a testament to the power of strategic collaboration and technological integration, epitomizing the core principles our FSP 3000 OLS was built upon: openness, scalability and cutting-edge performance. Through concerted efforts with our OIF partners, from renowned component manufacturers to key industry players, we’re crafting solutions that will provide the adaptability and optical prowess our customers need for the networking challenges they face,” commented Ryan Schmidt, GM of optical transport at Adtran. “By focusing on customized solutions and embracing an ecosystem-wide approach, Adtran is not only tackling current network complexities but also setting the stage for future advancements, ensuring that our customers will always stay ahead of the game.”
About the OIF demo
OIF to Showcase Interoperability at OFC 2024 with Nearly 50 Member Companies Collaborating to Address Unprecedented Demand for Next-Generation Network Solutions.
OIF’s interoperability demonstration at OFC 2024 will feature 47 member companies showcasing breakthrough solutions in speed, power and density to meet the growing demands of next-generation data center networking, AI/ML and disaggregation applications. See the solutions in 800ZR, 400ZR and OpenZR+ optics, Energy Efficient Interfaces (EEI) & Co-Packaging, Common Electrical I/O (CEI) channels and Common Management Interface Specification (CMIS) implementations that are playing a pivotal role in shaping the industry for the next decade. Experience these live and interactive demonstrations at booth #1323. For more information, visit: www.oiforum.com/meetings-events/oif-ofc-2024.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322753779/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom